A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
Status:
Enrolling by invitation
Trial end date:
2030-08-01
Target enrollment:
Participant gender:
Summary
The goal of this trial is to enable the collection of information about long-term safety and
clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants
will receive repeat doses of STAR-0215 for up to 5 years.